Week In Review: Sinovac's Privatization Offer Draws $459 Million Outside Bid

Shandong Sinobioway Biomedicine topped management's $402 million bid to privatize China vaccine maker Sinovac with a $459 million offer of its own. Sinovac is a Beijing vaccine company with legacy vaccines for hepatitis A and B.